WO2001082795A3 - Magnetic resonance imaging agents for the delivery of therapeutic agents - Google Patents

Magnetic resonance imaging agents for the delivery of therapeutic agents Download PDF

Info

Publication number
WO2001082795A3
WO2001082795A3 PCT/US2001/014665 US0114665W WO0182795A3 WO 2001082795 A3 WO2001082795 A3 WO 2001082795A3 US 0114665 W US0114665 W US 0114665W WO 0182795 A3 WO0182795 A3 WO 0182795A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
magnetic resonance
resonance imaging
agents
therapeutic agents
Prior art date
Application number
PCT/US2001/014665
Other languages
French (fr)
Other versions
WO2001082795A2 (en
Inventor
Thomas J Meade
Original Assignee
Res Corp Technologies Inc
Thomas J Meade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/716,178 external-priority patent/US6713045B1/en
Application filed by Res Corp Technologies Inc, Thomas J Meade filed Critical Res Corp Technologies Inc
Priority to EP01933128A priority Critical patent/EP1278553A2/en
Priority to AU2001259575A priority patent/AU2001259575A1/en
Priority to CA002407450A priority patent/CA2407450A1/en
Publication of WO2001082795A2 publication Critical patent/WO2001082795A2/en
Publication of WO2001082795A3 publication Critical patent/WO2001082795A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to novel magnetic resonance imaging contrast agents that report on physiological events in a conditional fashion and simultaneously detect the delivery and/or activation of a therapeutically active agent.
PCT/US2001/014665 2000-05-04 2001-05-04 Magnetic resonance imaging agents for the delivery of therapeutic agents WO2001082795A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01933128A EP1278553A2 (en) 2000-05-04 2001-05-04 Magnetic resonance imaging agents for the delivery of therapeutic agents
AU2001259575A AU2001259575A1 (en) 2000-05-04 2001-05-04 Magnetic resonance imaging agents for the delivery of therapeutic agents
CA002407450A CA2407450A1 (en) 2000-05-04 2001-05-04 Magnetic resonance imaging agents for the delivery of therapeutic agents

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US20181700P 2000-05-04 2000-05-04
US20210800P 2000-05-04 2000-05-04
US60/201,817 2000-05-04
US60/202,108 2000-05-04
US20322400P 2000-05-05 2000-05-05
US60/203,224 2000-05-05
US71617500A 2000-11-16 2000-11-16
US09/716,175 2000-11-16
US09/716,178 2000-11-16
US09/716,178 US6713045B1 (en) 1995-06-02 2000-11-16 Targeted magnetic resonance imaging agents for the detection of physiological processes

Publications (2)

Publication Number Publication Date
WO2001082795A2 WO2001082795A2 (en) 2001-11-08
WO2001082795A3 true WO2001082795A3 (en) 2002-05-02

Family

ID=27539457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014665 WO2001082795A2 (en) 2000-05-04 2001-05-04 Magnetic resonance imaging agents for the delivery of therapeutic agents

Country Status (4)

Country Link
EP (1) EP1278553A2 (en)
AU (1) AU2001259575A1 (en)
CA (1) CA2407450A1 (en)
WO (1) WO2001082795A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
EP1032430A2 (en) 1997-11-17 2000-09-06 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
EP4059925A1 (en) 2021-03-15 2022-09-21 Bayer Aktiengesellschaft New contrast agent for use in magnetic resonance imaging
EP4335840A1 (en) 2022-09-09 2024-03-13 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
EP4335462A1 (en) 2022-09-09 2024-03-13 Bayer AG Contrast agents for use in diagnostic computed tomography imaging

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038184A2 (en) * 1995-06-02 1996-12-05 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
WO1997036619A2 (en) * 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
WO1999021592A1 (en) * 1997-10-27 1999-05-06 California Institute Of Technology Magnetic resonance imaging agents for the delivery of therapeutic agents
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038184A2 (en) * 1995-06-02 1996-12-05 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
WO1997036619A2 (en) * 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
WO1999021592A1 (en) * 1997-10-27 1999-05-06 California Institute Of Technology Magnetic resonance imaging agents for the delivery of therapeutic agents
WO1999059640A2 (en) * 1998-05-16 1999-11-25 Bracco International B.V. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOATS REX A ET AL: "A Smart Magnetic Resonance Imaging Agent That Reports on Specific Enzymatic Activity", ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 36, no. 7, 1 April 1997 (1997-04-01), pages 726 - 728, XP002096505, ISSN: 0570-0833 *

Also Published As

Publication number Publication date
AU2001259575A1 (en) 2001-11-12
WO2001082795A2 (en) 2001-11-08
EP1278553A2 (en) 2003-01-29
CA2407450A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
IL154583A0 (en) Active agent delivery systems and methods for protecting and administering active agents
AU6311301A (en) Drug/drug delivery systems for the prevention and treatment of vascular disease
AU2001278319A1 (en) Amyloid targeting imaging agents and uses thereof
AU2002245629A1 (en) Stabilized therapeutic and imaging agents
WO2003074551A8 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
AU2001273341A1 (en) An implantable or insertable therapeutic agent delivery device
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
LT2000095A (en) Aerosolised active agent delivery
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
AU2001289308A1 (en) Targeted agents useful for diagnostic and therapeutic applications
IL162090A0 (en) Agents having a core peptide which derepresses iap-inhibited caspase and pharmaceutical compositionscontaining the same
CA2307332A1 (en) Magnetic resonance imaging agents for the delivery of therapeutic agents
WO2001082795A3 (en) Magnetic resonance imaging agents for the delivery of therapeutic agents
WO2002053090A3 (en) Medicinal association of a biguanine (metformin) and arginine
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
IL167406A (en) Lipophilic diesters of chelating agent and uses thereof for the preparation of medicaments for the inhibition of protease activity
AU1490801A (en) Targeted delivery of therapeutic and diagnostic moieties
EP1308509A4 (en) Novel physiologically active peptide and use thereof
EP1357129A4 (en) Novel physiologically active peptide and use thereof
HUP0301119A3 (en) Biologically active agent and drug
AU2001262699A1 (en) Biologically active agents and drugs
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
王垒 The structure and measurement of self-efficacy
EP1275659A4 (en) Novel physiologically active peptides and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2407450

Country of ref document: CA

Ref document number: 2001259575

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001933128

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001933128

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001933128

Country of ref document: EP